Last Updated : May 15, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Altace Plus Felodipine | Ramipril/felodipine extended release | Hypertension | Do not list | Complete | ||
| Vesicare | Solifenacin succinate | Bladder, overactive | Do not list | Complete | ||
| Nexavar | Sorafenib tablets | Cancer, Renal cell carcinoma | Do not list | Complete | ||
| Azilect | Rasagiline mesylate | Parkinson's disease | Do not list | Complete | ||
| Denavir | Penciclovir | Herpes labialis (cold sores) | Do not list | Complete | ||
| Sutent | Sunitinib malate | Cancer, Metastatic renal cell carcinoma | Do not list | Complete | ||
| Vantas | Histrelin acetate | Cancer, prostate | Do not list | Complete | ||
| Tramacet | Tramadol hydrochloride /acetaminophen | Acute pain | Do not list | Complete | ||
| Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | Do not list | Complete | ||
| Sebivo | Telbivudine | Hepatitis B (chronic) | Do not list | Complete |
Last Updated : May 15, 2024